Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Summary

This phase II trial studies how well nivolumab works with the DA-REPOCH chemotherapy regimen in treating patients with aggressive B-cell non-Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body?s immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as dose-adjusted rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride (DA-REPOCH), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab with DA-REPOCH may work better in treating patients with aggressive B-cell non-Hodgkin lymphoma.

Conditions

• Aggressive Non-Hodgkin Lymphoma
• Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
• Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Diffuse Large B-Cell Lymphoma
• High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
• High Grade B-Cell Lymphoma, Not Otherwise Specified
• Indolent Non-Hodgkin Lymphoma
• Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
• Transformed Non-Hodgkin Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Nivolumab

Given IV

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Give IV

Sponsors & Collaborators

• Bristol-Myers Squibb

  collaborator INDUSTRY

• David Bond, MD

  lead OTHER

Principal Investigators

• David A Bond, MD · Ohio State University Comprehensive Cancer Center

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-01-02

Primary Completion

2026-02-02

Completion

2026-12-31

FDA Drug

Yes

Countries

• United States

Study Locations